Your healthcare provider may need to give you antibiotic medicines to prevent or treat infections or fever while your blood cell counts are low. If your blood cell counts are too low, your healthcare provider may need to delay treatment with INQOVI, lower your dose of INQOVI, or in some cases give you a medicine to help treat low blood cell counts. Low blood counts (white blood cells, platelets, and red blood cells) are common with INQOVI but can also be serious and lead to infections that may be life-threatening.
Isentress copay card update#
Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.INQOVI may cause serious side effects, including: The company assumes no duty to update the information to reflect subsequent developments. The information contained in this website was current as of the date presented. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2021 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (No Duty to Update
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Risks and uncertainties include but are not limited to, general industry conditions and competition general economic factors, including interest rate and currency exchange rate fluctuations the impact of the recent global outbreak of novel coronavirus disease (COVID-19) the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally global trends toward health care cost containment technological advances, new products and patents attained by competitors challenges inherent in new product development, including obtaining regulatory approval the company’s ability to accurately predict future market conditions manufacturing difficulties or delays financial instability of international economies and sovereign risk dependence on the effectiveness of the company’s patents and other protections for innovative products and the exposure to litigation, including patent litigation, and/or regulatory actions. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. Private Securities Litigation Reform Act of 1995.
This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S.
0 kommentar(er)
